Neurelis
Neurelis has the license to bring the ROCK inhibitor NRL-1049 to trials specifically for CCM. The medicine is in Phase 1 clinical trials in the United States.
Ovid therapeutics/graviton bioscience
Ovid and Graviton are working to develop a ROCK2-specific inhibitor known as OV-888 (formerly GV101) to target CCM. Graviton developed the medicine and has licensed it to Ovid for clinical trials. A Phase 2 trial is on hold as Ovid integrates learnings from the atorvastatin and REC-994 trials.
repurposed medicines
Several medicines already on the market for other indications are seeking funding for Phase 2 or Phase 3 trials with our patients:
Propranolol
Propranolol has already completed a small multi-center safety trial in Italy. According to the research abstract:
Propranolol was safe and well tolerated in this population. Propranolol might be beneficial for reducing the incidence of clinical events in people with symptomatic familial cerebral cavernous malformations, although this trial was not designed to be adequately powered to investigate efficacy. A definitive phase 3 trial of propranolol in people with symptomatic familial cerebral cavernous malformations is justified.
Funding is being sought through multiple European agencies.
Low-dose Aspirin
While it seems counter-intuitive, some researchers believe that antithrombotic medicines do not increase hemorrhage risk and that low-dose aspirin may offer protective effects against hemorrhage. Multiple retrospective case series studies have offered supporting evidence. Funding is being sought in the UK for a clinical trial.
Rapamycin
Rapamycin, also known as sirolimus, is an mTOR inhibitor used in multiple disorders involving vascular malformations and has been tested in patients with other slow-flow vascular malformations. It has been tried in acute mouse models of CCM and appears to have an effect. Funding for a clinical trial is being sought in the US and a clinical trial has begun in China.
3.31.2025
